Romo Tammy sold $2.0M of THC

Romo Tammy sold 7,422 shares of TENET HEALTHCARE CORP (THC) at an average of $263.03 ($260.83–$264.15, $1.95M total) across 2 trades over 2026-08-06 to 2026-08-07.

Original reporting
SEC EDGAR · Romo Tammy
Published Aug 11, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure updates the record of insider activity and can influence short-term sentiment, but it does not provide new information about Tenet’s operations, financial results, or guidance.

02

Market read

Traders may monitor insider selling as a sentiment input, but the filing alone is not a fundamental catalyst.

03

What to watch

Insider sales often reflect diversification, taxes, or pre-scheduled liquidity needs; the article provides no reason for the sale or any link to company performance.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-10 for trades dated 2026-08-06 to 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare Corp, reported by director Romo Tammy.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Romo Tammy filed Form 4 showing an open-market sale of 7,422 shares at about $260.83 to $264.15.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan and no accompanying operational or guidance change disclosed in the text.

Market effects

No sector-level implications are provided; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is not tied to a stated 10b5-1 plan in the text, some traders may overinterpret it as bearish despite being a small, routine insider transaction.

Key entities

  • Tenet Healthcare Corp

    Subject of the Form 4 insider transaction disclosure.

  • Romo Tammy

    Director who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.